Healthcare company Organon (NYSE:OGN) said on Monday that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD).
The transaction is subject to Hart-Scott-Rodino review and US Food and Drug Administration (FDA) approval of alternate supply chain entities.
MIUDELLA, the first hormone-free copper IUD approved in the United States in 40 years, received FDA approval in February 2025 for up to three years of pregnancy prevention but is not yet commercially available. The device features a flexible frame and a preloaded inserter with a 3.7mm tapered insertion tube.
Under the deal, Organon will pay USD27.5m at closing, with potential sales-based milestone payments of up to USD505m and tiered double-digit royalties on net sales.
Laronix and Greater Baltimore Medical Center launch Laronix MIRA Voice investigational study
BD receives CE Mark for Revello vascular covered stent
GAIA and Daiichi Sankyo Europe partner on digital therapeutic for cardiovascular care
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
BD receives FDA clearance for Surgiphor 1000mL irrigation system
Galderma secures EU, US and Canada approval for new Restylane syringe
Organon licenses MIUDELLA IUD from Sebela Pharmaceuticals
Advita Ortho updates Chime clinical exchange application
Philips launches InkSpace Imaging Snuggle coil for 3.0T MRI systems
Realheart secures European patent for artificial heart technology
Median Technologies secures FDA clearance for AI lung cancer screening software
Eli Lilly to invest over USD3.5bn in new Pennsylvania plant
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Zylox-Tonbridge agrees staged acquisition of Germany's Optimed